Salarius Pharmaceuticals Inc
NASDAQ:SLRX
Salarius Pharmaceuticals Inc
NASDAQ:SLRX
Price:
0.8606
USD
21.21%
Market Cap:
$5m
Balance Sheet
Balance Sheet Decomposition
Salarius Pharmaceuticals Inc
Salarius Pharmaceuticals Inc
Balance Sheet Decomposition is not available for
Salarius Pharmaceuticals Inc
Salarius Pharmaceuticals Inc
Balance Sheet
Salarius Pharmaceuticals Inc
Salarius Pharmaceuticals Inc
Currency: USD
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & Cash Equivalents |
34
|
67
|
22
|
19
|
10
|
4
|
11
|
29
|
12
|
6
|
2
|
|
| Cash Equivalents |
34
|
67
|
22
|
19
|
10
|
4
|
11
|
29
|
12
|
6
|
2
|
|
| Short-Term Investments |
0
|
25
|
39
|
14
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
4
|
0
|
2
|
0
|
0
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
4
|
0
|
2
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
1
|
1
|
1
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Total Current Assets |
34
|
92
|
62
|
35
|
10
|
5
|
16
|
30
|
15
|
7
|
3
|
|
| PP&E Net |
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| PP&E Gross |
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Goodwill |
0
|
0
|
0
|
0
|
0
|
9
|
9
|
9
|
0
|
0
|
0
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Assets |
0
|
0
|
0
|
0
|
0
|
9
|
9
|
9
|
0
|
0
|
0
|
|
| Total Assets |
36
N/A
|
95
+167%
|
63
-34%
|
35
-45%
|
10
-70%
|
14
+34%
|
25
+79%
|
41
+64%
|
15
-64%
|
7
-55%
|
3
-54%
|
|
| Liabilities | ||||||||||||
| Accounts Payable |
1
|
1
|
1
|
2
|
0
|
2
|
2
|
2
|
3
|
1
|
1
|
|
| Accrued Liabilities |
0
|
2
|
3
|
4
|
1
|
0
|
0
|
1
|
1
|
0
|
0
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
1
|
3
|
4
|
6
|
1
|
3
|
3
|
2
|
4
|
1
|
2
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
1
N/A
|
3
+157%
|
4
+35%
|
6
+51%
|
1
-81%
|
3
+199%
|
3
-16%
|
2
-24%
|
4
+102%
|
1
-70%
|
2
+16%
|
|
| Equity | ||||||||||||
| Common Stock |
41
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
8
|
37
|
77
|
111
|
133
|
12
|
19
|
32
|
64
|
76
|
82
|
|
| Additional Paid In Capital |
1
|
129
|
136
|
140
|
142
|
23
|
42
|
71
|
74
|
82
|
83
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
34
N/A
|
92
+167%
|
59
-36%
|
29
-51%
|
9
-68%
|
11
+14%
|
22
+109%
|
39
+75%
|
10
-73%
|
5
-49%
|
2
-71%
|
|
| Total Liabilities & Equity |
36
N/A
|
95
+167%
|
63
-34%
|
35
-45%
|
10
-70%
|
14
+34%
|
25
+79%
|
41
+64%
|
15
-64%
|
7
-55%
|
3
-54%
|
|
| Shares Outstanding | ||||||||||||
| Common Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Preferred Shares Outstanding |
30
|
30
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Switch to:
Switch to:
See Also
Discover More
